VectivBio Holding AG
UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)
In thousands of United States dollars ("USD") | ||||||||||||||
Six Month Ended June 30, | ||||||||||||||
2021 | 2020 | |||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||
Research and development expenses | (26,494 | ) | (10,660) | |||||||||||
General and administrative expenses | (19,097 | ) | (5,405) | |||||||||||
Operating loss | (45,591) | (16,065) | ||||||||||||
Finance income | — | 15 | ||||||||||||
Finance expense | (23) | (1,096) | ||||||||||||
Foreign exchange differences, net | 496 | (517) | ||||||||||||
Loss before income taxes | (45,118) | (17,677) | ||||||||||||
Income taxes | — | — | ||||||||||||
Net loss | (45,118) | (17,677) | ||||||||||||
Remeasurement of net pension liabilities | 508 | (511) | ||||||||||||
Total items that will not be reclassified subsequently to profit or loss | 508 | (670) | ||||||||||||
Exchange differences arising on translation of foreign operations | (113) | (670) | ||||||||||||
Total items that may be reclassified subsequently to profit or loss | (113) | (670) | ||||||||||||
Total other comprehensive loss, net of income tax | 395 | (1,181) | ||||||||||||
Total comprehensive loss | (44,723) | (18,858) | ||||||||||||
LOSS PER SHARE | ||||||||||||||
Basic and diluted loss per share (in USD) | (2.08) | (1.85) | ||||||||||||